Table of Content

Chapter 1: INTRODUCTION
1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits to the Stakeholders
1.4. Research Methodology
1.4.1. Primary Research
1.4.2. Secondary Research
1.4.3. Analyst Tools and Models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
Chapter 3: MARKET OVERVIEW
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Impacting Factors
3.2.2. Top Investment Pockets
3.3. Porter’s Five Forces Analysis
3.4. Market Dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
3.5. COVID-19 Impact Analysis on the market
Chapter 4: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS
4.1. Overview
4.1.1. Market Size and Forecast, By Drug class
4.2. Monoclonal antibodies
4.3. Intravenous immunoglobulin
4.4. Others
Chapter 5: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP
5.1. Overview
5.1.1. Market Size and Forecast, By Age group
5.2. Below 55 years
5.3. Above 55 years
Chapter 6: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market Size and Forecast, By Distribution channel
6.2. Hospital pharmacies
6.3. Drug store and retail pharmacies
6.4. Online providers
Chapter 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top player positioning, 2022
Chapter 8: COMPANY PROFILES
8.1. Novartis AG
8.1.1. Company overview
8.1.2. Key Executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. AbbVie Inc.
8.2.1. Company overview
8.2.2. Key Executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Biogen
8.3.1. Company overview
8.3.2. Key Executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. AstraZeneca
8.4.1. Company overview
8.4.2. Key Executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. GlaxoSmithKline PLC
8.5.1. Company overview
8.5.2. Key Executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Hoffmann-La Roche Ltd
8.6.1. Company overview
8.6.2. Key Executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Merck & Co., Inc.
8.7.1. Company overview
8.7.2. Key Executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. CSL Behring LLC
8.8.1. Company overview
8.8.2. Key Executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Baxter International
8.9.1. Company overview
8.9.2. Key Executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Bristol-Myers Squibb Company
8.10.1. Company overview
8.10.2. Key Executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments



List of Figures

LIST OF FIGURES
FIGURE 01. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET (2023-2032)
FIGURE 04. PORTER FIVE-1
FIGURE 05. PORTER FIVE-2
FIGURE 06. PORTER FIVE-3
FIGURE 07. PORTER FIVE-4
FIGURE 08. PORTER FIVE-5
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 10. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET,BY DRUG CLASS, 2022 ($MILLION)
FIGURE 11. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET,BY AGE GROUP, 2022 ($MILLION)
FIGURE 12. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET,BY DISTRIBUTION CHANNEL, 2022 ($MILLION)
FIGURE 13. TOP WINNING STRATEGIES, BY YEAR
FIGURE 14. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 15. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 16. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 17. COMPETITIVE DASHBOARD
FIGURE 18. COMPETITIVE HEATMAP: MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET
FIGURE 19. TOP PLAYER POSITIONING, 2022
FIGURE 20. NOVARTIS AG: NET SALES, 2020-2022*?($MILLION)
FIGURE 21. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 22. NOVARTIS AG: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 23. ABBVIE INC.: NET SALES, 2020-2022*?($MILLION)
FIGURE 24. ABBVIE INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 25. ABBVIE INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 26. BIOGEN: NET SALES, 2020-2022*?($MILLION)
FIGURE 27. BIOGEN: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 28. BIOGEN: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 29. ASTRAZENECA: NET SALES, 2020-2022*?($MILLION)
FIGURE 30. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 31. ASTRAZENECA: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 32. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022*?($MILLION)
FIGURE 33. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 34. GLAXOSMITHKLINE PLC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 35. HOFFMANN-LA ROCHE LTD: NET SALES, 2020-2022*?($MILLION)
FIGURE 36. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 37. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 38. MERCK & CO., INC.: NET SALES, 2020-2022*?($MILLION)
FIGURE 39. MERCK & CO., INC.: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 40. MERCK & CO., INC.: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 41. CSL BEHRING LLC: NET SALES, 2020-2022*?($MILLION)
FIGURE 42. CSL BEHRING LLC: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 43. CSL BEHRING LLC: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 44. BAXTER INTERNATIONAL: NET SALES, 2020-2022*?($MILLION)
FIGURE 45. BAXTER INTERNATIONAL: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 46. BAXTER INTERNATIONAL: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)
FIGURE 47. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022*?($MILLION)
FIGURE 48. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2022 (%)
FIGURE 49. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY GEOGRAPHY, 2022 (%)

List of Tables

LIST OF TABLES
TABLE 01. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DRUG CLASS, 2022-2032 ($MILLION)
TABLE 02. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY AGE GROUP, 2022-2032 ($MILLION)
TABLE 03. MIDDLE EAST AND AFRICA MYASTHENIA GRAVIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 04. NOVARTIS AG: KEY EXECUTIVES
TABLE 05. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 06. NOVARTIS AG: OPERATING SEGMENTS
TABLE 07. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 08. NOVARTIS AG: KEY STRATERGIES
TABLE 09. ABBVIE INC.: KEY EXECUTIVES
TABLE 10. ABBVIE INC.: COMPANY SNAPSHOT
TABLE 11. ABBVIE INC.: OPERATING SEGMENTS
TABLE 12. ABBVIE INC.: PRODUCT PORTFOLIO
TABLE 13. ABBVIE INC.: KEY STRATERGIES
TABLE 14. BIOGEN: KEY EXECUTIVES
TABLE 15. BIOGEN: COMPANY SNAPSHOT
TABLE 16. BIOGEN: OPERATING SEGMENTS
TABLE 17. BIOGEN: PRODUCT PORTFOLIO
TABLE 18. BIOGEN: KEY STRATERGIES
TABLE 19. ASTRAZENECA: KEY EXECUTIVES
TABLE 20. ASTRAZENECA: COMPANY SNAPSHOT
TABLE 21. ASTRAZENECA: OPERATING SEGMENTS
TABLE 22. ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 23. ASTRAZENECA: KEY STRATERGIES
TABLE 24. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 25. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 26. GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE 27. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 28. GLAXOSMITHKLINE PLC: KEY STRATERGIES
TABLE 29. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
TABLE 30. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
TABLE 31. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
TABLE 32. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
TABLE 33. HOFFMANN-LA ROCHE LTD: KEY STRATERGIES
TABLE 34. MERCK & CO., INC.: KEY EXECUTIVES
TABLE 35. MERCK & CO., INC.: COMPANY SNAPSHOT
TABLE 36. MERCK & CO., INC.: OPERATING SEGMENTS
TABLE 37. MERCK & CO., INC.: PRODUCT PORTFOLIO
TABLE 38. MERCK & CO., INC.: KEY STRATERGIES
TABLE 39. CSL BEHRING LLC: KEY EXECUTIVES
TABLE 40. CSL BEHRING LLC: COMPANY SNAPSHOT
TABLE 41. CSL BEHRING LLC: OPERATING SEGMENTS
TABLE 42. CSL BEHRING LLC: PRODUCT PORTFOLIO
TABLE 43. CSL BEHRING LLC: KEY STRATERGIES
TABLE 44. BAXTER INTERNATIONAL: KEY EXECUTIVES
TABLE 45. BAXTER INTERNATIONAL: COMPANY SNAPSHOT
TABLE 46. BAXTER INTERNATIONAL: OPERATING SEGMENTS
TABLE 47. BAXTER INTERNATIONAL: PRODUCT PORTFOLIO
TABLE 48. BAXTER INTERNATIONAL: KEY STRATERGIES
TABLE 49. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
TABLE 50. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
TABLE 51. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
TABLE 52. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
TABLE 53. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATERGIES